Allergy Therapeutics (AGY)

 

Latest News

Allergy Therapeutics (AGY): Opening the door to registration

Hardman & Co Research Hardman & Co Research: Allergy Therapeutics (AGY): Opening the door to registration 21-May-2018 / 12:25 GMT/BST Hardman & Co Research: Opening the door to registration AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro (PQ) Grass, the subcutaneous allergy immunotherapy (SCI...

Allergy Therapeutics grass allergy product meets primary objectives

Allergy Therapeutics said Monday a study to explore the safety and response of its grass allergy product drug met its prim...

Positive top-line results from Grass Ph II study

RNS Number: 6504O Allergy Therapeutics PLC 21 May 2018 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Allergy Therapeutics announces positive top-line results from its Grass MATA MPL Phase II dose ranging study - Primary endpoint met with highly statistically significant dose-response relationship established - - Optimal Phase III dose identi...

Publication of MCT Adjuvant Data

RNS Number: 8725N Allergy Therapeutics PLC 14 May 2018 Al l e r g y Th e r a p e u ti cs p l c (" A l l e r gy T he r a peu t i cs" or t he " Group " ) Allergy Therapeutics Publishes New Data Validating Mode of Action and Unique Adjuvant Properties of its Patented Adjuvant, Microcrystalline Tyrosine (MCT ), in The Journal of Immunology Novel Findings Further...

All News

DateHeadlineSource
03-08-12Markets: FTSE 100 climbs higher on FridayInteractive Investor
18-04-12Markets: FTSE 100 uncertain on WednesdayInteractive Investor
06-12-11Markets: FTSE 100 flat on TuesdayInteractive Investor
26-04-11Markets: Manufacturing data lifts FTSE 100Interactive Investor
26-04-11FDA approval lifts shares in Allergy TherapeuticsInteractive Investor
28-03-11Markets: FTSE 100 trims gains on MondayInteractive Investor

RSS feeds

  • Editorial news feed for LSE:AGY Editorial
  • Regulatory news feed for LSE:AGY Regulatory